FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances …
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share the latest advancements in food allergy and anaphylaxis research. The event featured impactful sessions, debates, workshops, and plenary discussions, highlighting new evidence and the importance of ...
QUANTRO Therapeutics achieves breakthrough in transcriptomic …
Jan 7, 2025 · EQS-News: QUANTRO Therapeutics GmbH / Key word(s): Conference/Research UpdateQUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening 07.01.2025 / 14:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Pr...
ACI Group Introduces Hytolive and Vintera Sustainable …
Dec 11, 2024 · ACI Group is shining a spotlight on heart health with the introduction of two new sustainably sourced Mediterranean ingredients to its growing portfolio from nutrition specialist Alvinesa - Hytolive® and Vintera™. Hytolive is an extra virgin olive oil (EVOO) extract derived from the olive fruit, as opposed to ...
ViiV Healthcare announces CHMP positive opinion for Vocabria
Dec 16, 2024 · Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year; At just 65% globally, treatment coverage for 10 – 19-year-olds living with HIV is lagging behind UNAIDS’s target, demonstrating need to improve HIV care options for young people
Evaluate Releases 2025 Preview for Pharma Market
Jan 7, 2025 · Report signals industry-wide growth headlined by obesity and oncology therapy areas. LONDON – [7 th January 2025] – Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.. The 2025 Preview, drawn from Evaluate Pharma and Evaluate Omnium, projects that, while the ...
BSI Software announces new Board of Directors - PharmiWeb.com
(PresseBox) (Baden, 08.01.2025) BSI Software has a new Board of Directors. The General Meeting elected Léo Apotheker as the new Chairman of the Board, along with the other board members, thereby paving the way for a secure future.
Lung cancer test predicts survival in early stages better than …
Jan 9, 2025 · Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed treatment decisions for people with stage 1 lung ...
NICE RECOMMENDS LYNPARZA (OLAPARIB) TO TREAT GERMLINE …
Jan 9, 2025 · Today, AstraZeneca announced that Lynparza (olaparib) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for NHS use in England and Wales to treat adults with HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations ...
Thermo Fisher Scientific’s Olink Platform Selected for World’s …
6 days ago · Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 ...
HUTCHMED to Receive Milestone Payment from Takeda following …
Dec 13, 2024 · — US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade —. Hong Kong, Shanghai & Florham Park, NJ — Friday, December 13, 2024: HUTCHMED (China ...